MedPath

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

Conditions
Patients
Registration Number
NCT05088161
Lead Sponsor
The Affiliated Hospital of Qingdao University
Brief Summary

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

Detailed Description

This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients of Chinese nationality, age and gender are not limited.
  • Pathologically confirmed pancreatic cancer patients.
  • Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer.
  • Clinical diagnostic information was complete three months before sampling.
Exclusion Criteria
  • Patients with a second primary tumor.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Differentially expressed proteins in tumor and paracancer tissues180 Days

Two dimensional gel electrophoresis, mass spectrometry and other techniques were used to separate and compare pancreatic cancer tissues and normal adjacent tissues to search for differentially expressed proteins.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Phase I Clinical Research Center

🇨🇳

Qingdao, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath